Hubei Biocause Heilen Pharmaceutical Co., Ltd.

Equities

301211

CNE100005782

Pharmaceuticals

End-of-day quote Shenzhen S.E. 23:00:00 30/05/2024 BST 5-day change 1st Jan Change
16.4 CNY +0.18% Intraday chart for Hubei Biocause Heilen Pharmaceutical Co., Ltd. -4.15% -24.60%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Announces Implementation of Final A Share Cash Dividend for 2023, Payable on 06 June 2024 CI
Biocause Heilen Pharmaceutical's Cardiovascular Drug Passes Chinese Drug Regulator's Evaluation MT
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Approves Dividend for the Year 2023 CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd.(XSEC:301211) added to S&P Global BMI Index CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Approves Final Cash Dividend for the Year 2022, Payment Date Is 31 May 2023 CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2022 CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Hubei Biocause Heilen Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Chart Hubei Biocause Heilen Pharmaceutical Co., Ltd.
More charts
Hubei Biocause Heilen Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of chemical Active Pharmaceutical Ingredients (API) and preparation products. The Company's products can be divided into non-steroidal anti-inflammatory, cardiovascular and anti-tumor. The API products include Ibuprofen, D-Ibuprofen, Torasemide, Milrinone, Abiraterone Acetate, Granisetron Hydrochloride, Fludarabine Phosphate and others. The preparation products include Ibuprofen Granules, Ibuprofen Tablets, Ibuprofen Pseudoephedrine Tablets, Oxaprozin Enteric Coated Tablets, Oxaprozin Enteric Coated Capsules, Torasemide Tablets and others. The Company's products are exported to India, the United States, the European Union, South Korea and other countries.
More about the company
  1. Stock Market
  2. Equities
  3. 301211 Stock
  4. News Hubei Biocause Heilen Pharmaceutical Co., Ltd.
  5. Biocause Heilen Pharmaceutical's Cardiovascular Drug Passes Chinese Drug Regulator's Evaluation